Sunshine Heart's C-Pulse(R) System Feasibility Study Data

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Sunshine Heart's C-Pulse(R) System Feasibility Study Data Published in JACC

EDEN PRAIRIE, Minn., Oct. 7, 2014 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (Nasdaq: SSH ) today announced the results of its feasibility study entitled "Ambulatory Extra-Aortic Counterpulsation in Patients with Moderate to Severe Chronic Heart Failure," published in the Journal of American College of Cardiology Heart Failure (JACC HF) . The study showed that the use of the C-Pulse System in Class III and ambulatory Class IV heart failure (HF) patients is feasible while providing preliminary indications of safety and improvements in functional status and health-related quality of life (QOL).

William Abraham, M.D., director of the Division of Cardiovascular Medicine at The Ohio State University Medical Center, said, "There are numerous challenges with the current treatment options of Class III and ambulatory Class IV heart failure patients. Surgical treatments available are often last resort, high risk and invasive. The C-Pulse System addresses these challenges , is less invasive, has a lower risk profile and can be placed in patients too sick to be on optimal medical therapy alone, but not so sick that they require mechanical circulatory support or a heart transplant."

The C-Pulse System feasibility study was a prospective, open-label, single-arm 20-patient study approved by the U.S. Food and Drug Administration under an Investigational Device Exemption (IDE) and undertaken at seven centers in North America. Following baseline testing, eligible patients who had New York Heart Association (NYHA) Class III or ambulatory Class IV HF underwent implantation of the C-Pulse System between April 15, 2009 and June 20, 2011. No anti-coagulants were required with use of the C-Pulse System, reducing the risk of bleeding complications; and the location of the implanted cuff around the aorta mitigated the risk of intra-vascular clotting concerns.

At 6 months, C-Pulse produced statistically significant improvements in NYHA Class (3.1 to 1.9, p=0.0005), as well as in two validated QOL instruments including the Minnesota Living with Heart Failure questionnaire (63.6 to 40.2, p=0.0005) and the Kansas City Cardiomyopathy Questionnaire (43.6 to 65.6, p=0.0002). The 6 Minute Walk Distance improved at 6 months with statistically significant improvement at one year (289.7 to 336.5, p=0.0425). There was no change in peak VO 2 (14.5 to 13.1, p=0.2612).  Importantly, over the 12 months following initial placement of the C-Pulse device, only 3 of the 20 implanted patients (15%) had 5 adjudicated heart failure related hospitalizations, none which occurred within 30 days of implant.

There were no 30-day operative deaths reported in the study. Additionally, there were no neurological events, no device related bleeding events, no stroke events, and no myocardial infarctions through 12 months. At 12 months, there was one adjudicated device-related death. The device-related death was attributed to complications arising from a sternal wound infection in a patient who underwent repeated sternotomies and attempted sternectomy. Exit-site infections were also observed in 8 patients which prompted the Company to incorporate changes to mitigate this in the future.

Dr. Abraham added, "Although the study was not designed or powered to demonstrate efficacy, the magnitude of patient improvements using the C-Pulse System is clinically meaningful when compared to prior drug and device studies in heart failure. In addition, there were patients that were successfully weaned from the device, an early indication that C-Pulse may have reversed or prevented the progression of their disease , preventing the need for an LVAD or a heart transplant."

Based on review of the feasibility study data, a prospective, randomized, controlled study designed to demonstrate and extend these observations was approved by the FDA in November 2012 (COUNTER HF™). With stricter guidelines for exit site management and use of a minimally-invasive implant procedure, this pivotal study is currently underway in the U.S.

"The promising results of the feasibility study suggest that the C-Pulse System may lead to improvements in the quality of life of patients suffering from Class III and ambulatory Class IV heart failure and demonstrate that the C-Pulse system may offer an advantage over other treatment options," said David Rosa, Chief Executive Officer of Sunshine Heart. "We continue to advance our COUNTER HF™ U.S. pivotal study and our European OPTIONS HF study."

Clips to Interview with William Abraham, M.D.:

Other Relevant Videos:

About the C-Pulse ® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counterpulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient's current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility study, we also believe that some patients treated with our C-Pulse System will be able to be weaned from using the device due to sustained improvement in their heart failure condition as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.

About Sunshine ® Heart

Sunshine Heart, Inc. (Nasdaq: SSH ) is an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure.  Sunshine Heart has completed an approved U.S. Food and Drug Administration (FDA) feasibility clinical study of the C-Pulse System and presented the results in November 2011.  In March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE) application.  Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its pivotal study.  In July 2012, Sunshine Heart received CE Mark approval for its C-Pulse System in Europe.  Sunshine Heart is a Delaware corporation headquartered in Minneapolis with a wholly owned subsidiary in Australia.  The Company has been listed on the NASDAQ Capital Market since February 2012.  

Forward-Looking Statements

Certain statements in this release are forward-looking statements that are based on management's beliefs, assumptions, expectations, and information currently available to management.  All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including, without limitation, future clinical study activities and results including patient enrollment in studies. These forward-looking statements are subject to numerous risks and uncertainties, including, without limitation, the possibility that our clinical studies do not meet their enrollment goals, meet their endpoints or otherwise fail, that regulatory authorities do not accept our application or approve the marketing of the C-Pulse System, the possibility that we may be unable to raise the funds necessary for the development and commercialization of our products, that we may not be able to commercialize our products successfully in the EU and the other risk factors described under the caption "Risk Factors" and elsewhere in our filings with the SEC.  You should not place undue reliance on forward-looking statements because they speak only as of the date when made and may turn out to be inaccurate. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Investor: Candice Knoll Blueprint Life Science Group T: +1-415-375-3340 Jeff Mathiesen Chief Financial Officer Sunshine Heart, Inc. T: +1-952-345-4200 Media: David Schull Russo Partners T: +1-212-845-4271 Andreas Marathovouniotis Russo Partners T: +1-212-845-4235

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 269

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
NaLA Pushes for Stronger Lifeline Fraud Measures

Updated Category News Views 89

Here's the thing about the Lifeline program: it's meant to be a lifeline, not a loophole for the crafty and unscrupulous. The National Lifeline Association (NaLA) is slamming the table, demanding that the Senate Commerce Committee put some real muscle into preventing fraud. Why the Urgency on Lifeline Fraud? NaLA’s got its sights on a more robust defensive line against...

Continue Reading
Cardio Partners Hits a Million Milestone with Red Cross

Updated Category News Views 121

One Million Trained, One Million Prepared Ah, a million sounds like just another number, doesn't it? But when someone's life hangs in the balance, those are a million folks ready to jump in and act. Cardio Partners has hit this mighty milestone in CPR, AED, and First Aid training, gaining a pat on the back from none other than the American Red Cross. It's a testament,...

Continue Reading
Blueprint Strengthens Team with New Capital Markets Director

Updated Category News Views 114

Blueprint Bolsters Its Ranks Hiring Caitlin Novak as Managing Director marks a pivotal step for Blueprint Healthcare Real Estate Advisors. They aren't just swapping pawns; they're making a statement, beefing up their capital markets strategy with a heavy hitter seasoned in steering around fiscal pitfalls. Novak isn’t some rookie wet behind the ears—she's clocked more...

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 162

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 186

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
Grupo Supervielle's Q3 2026: Back to Growth Path

Updated Category News Views 66

Mounting Momentum in Loans and Asset Quality Grupo Supervielle, the Argentine financial player, has been tinkering with its gears to navigate the bumpy roads of 2026. In the third quarter, the company reports a gentle uptick in net loans—up 1.3% sequentially. This was particularly felt in September, with loans increasing 3.7%. Holding Their Own Against the Industry...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 77

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 202

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading

Top 5 Most Recently Viewed Articles

CNB Community Bancorp Raises Quarterly Dividend to $0.30

Updated Category News Views 103

CNB Community Bancorp Declares Increased Cash Dividend CNB Community Bancorp, Inc. has recently made an exciting announcement regarding its financial strategy. The Board of Directors has officially declared a quarterly cash dividend of $0.30 per share for the company’s common stock. This new dividend reflects an increase of $0.01 per share compared to the previous...

Continue Reading
Exciting Primark Store Opening at Wolfchase Galleria

Updated Category News Views 410

Exciting Primark Store Opening at Wolfchase Galleria Primark, a global favorite in fashion retail, is set to make a splash in the U.S. by opening its first Tennessee store. Located at Wolfchase Galleria, this grand opening signifies a pivotal moment for the brand, as it marks their 31st U.S. location, proudly spreading across various states. With the new store covering...

Continue Reading
Continuous Gold Processing at North Bay Resources' Mill

Updated Category News Views 145

Exciting Developments at North Bay Resources North Bay Resources, Inc. (the “Company” or “North Bay”) (OTC: NBRI) is thrilled to announce the successful continuous operations of its Bishop Gold Mill. Following significant upgrades made recently, the mill has been running successfully for up to nine hours a day. This achievement has led to the processing of...

Continue Reading
Insider Stock Purchase Highlights Marriott Vacations Growth Potential

Updated Category News Views 130

Insight into Recent Stock Transactions A significant insider purchase was reported by Lizanne Galbreath, a Board Member at Marriott Vacations (NYSE: VAC), showcasing her confidence in the company’s future. This transaction involved the acquisition of 5,500 shares, valued at approximately $255,805, as submitted in a Form 4 filing to the SEC. Such transactions often...

Continue Reading
Market Reaction to Potential Fed Chair Nomination Shakes Up Trends

Updated Category News Views 161

Market Reaction to Potential Fed Chair Nomination Recent market trends show significant fluctuations as rumors circulate about President Trump’s forthcoming announcement regarding a new chairman for the Federal Reserve. The spotlight is on former Fed Governor Kevin Warsh, expected to be nominated later today, which sends ripples through the gold and dollar markets....

Continue Reading